Catherine Smith


Leukemia researcher and lifelong San Francisco Giants fan

About me

Dr. Catherine Smith is a hematologist-oncologist who cares for patients with acute leukemia and myeloproliferative neoplasms (blood cancers that occur when the body overproduces one of the blood cell types). She specializes in acute myeloid leukemia (also known as acute myelogenous leukemia or AML), a cancer of the blood and bone marrow that spreads rapidly. She has a particular interest in treating AML patients who have mutations in the FLT3 gene, which is involved in leukemia cell growth, division and survival and is a factor that may be useful in making a prognosis.

Smith's research focuses on understanding why some patients do not respond to AML therapies and on developing new strategies to treat these patients.

A San Francisco native, Smith earned her medical degree from Duke University and completed a residency in internal medicine at Brigham and Women's Hospital. She then completed a fellowship in hematology and oncology at UCSF.

  • Education

    Duke University, 2002

  • Residencies

    Brigham and Women's Hospital, Internal Medicine, 2005

  • Fellowships

    UCSF, Hematology-Oncology, 2009

  • Board Certifications

    Hematology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

  • Languages


My patients inspire me to do my best every day.

Clinics I work with

Hematology, Blood & Marrow Transplant, and Cellular Therapies (HBC) Program

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

My reviews


Overall Experience
91 Reviews
Explained things in a way that was easy to understand
91 Reviews
Did the doctor pay attention to your concerns
91 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
89 Reviews
Knew the important information about your medical history
91 Reviews
The provider showed respect for what you had to say
91 Reviews
The provider spent enough time with me
91 Reviews
Decorative Caduceus

Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Safety Assessments include frequency of adverse events (AEs) in percentage (%)